

## **Genome-wide association studies and multi-omics integrative analysis reveal novel loci and their molecular mechanisms for circulating polyunsaturated, monounsaturated, and saturated fatty acids**

Yitang Sun<sup>1</sup>, Huifang Xu<sup>1</sup>, Kaixiong Ye<sup>1,2,\*</sup>

<sup>1</sup>Department of Genetics, University of Georgia, Athens, GA, USA

<sup>2</sup>Institute of Bioinformatics, University of Georgia, Athens, GA, USA

\* Correspondence: Dr. Kaixiong Ye ([Kaixiong.Ye@uga.edu](mailto:Kaixiong.Ye@uga.edu))

## 1 **Abstract**

2 Previous genome-wide association studies (GWAS) have identified genetic loci associated with  
3 the circulating levels of FAs, but the biological mechanisms of these genetic associations remain  
4 largely unexplored. Here, we conducted GWAS to identify additional genetic loci for 19  
5 circulating fatty acid (FA) traits in UK Biobank participants of European ancestry (N = 239,268)  
6 and five other ancestries (N = 508 – 4,663). We leveraged the GWAS findings to characterize  
7 genetic correlations and colocalized regions among FAs, explore sex differences, examine FA  
8 loci influenced by lipoprotein metabolism, and apply statistical fine-mapping to pinpoint putative  
9 causal variants. We integrated GWAS signals with multi-omics quantitative trait loci (QTL) to  
10 reveal intermediate molecular phenotypes mediating the associations between the genetic loci  
11 and FA levels. Altogether, we identified 215 significant loci for polyunsaturated fatty acids  
12 (PUFAs)-related traits in European participants, 163 loci for monounsaturated fatty acids  
13 (MUFAs)-related traits, and 119 loci for saturated fatty acids (SFAs)-related traits, including 70,  
14 61, and 54 novel loci, respectively. A novel locus for total FAs, the percentage of omega-6  
15 PUFAs in total FAs, and total MUFAs (around genes *GSTT1/2/2B*) overlapped with QTL signals  
16 for all six molecular phenotypes examined, including gene expression, protein abundance, DNA  
17 methylation, splicing, histone modification, and chromatin accessibility. Across 19 FA traits, 65%  
18 of GWAS loci overlapped with QTL signals for at least one molecular phenotype. Our study  
19 identifies novel genetic loci for circulating FA levels and systematically uncovers their  
20 underlying molecular mechanisms.

21

22 **Keywords:** GWAS, polyunsaturated fatty acids, fatty acids, xQTL, multi-omics

## 23 **Introduction**

24 Polyunsaturated fatty acids (PUFAs), monounsaturated fatty acids (MUFAs), and  
25 saturated fatty acids (SFAs) have been implicated in various diseases.<sup>1-3</sup> Evidence from  
26 epidemiological and genetic studies indicates that PUFAs, especially omega-3 PUFAs, are  
27 associated with reduced risks of various diseases or mortality by modifying metabolism and  
28 inflammation.<sup>4-7</sup> Circulating fatty acid (FA) levels are influenced by environmental and genetic  
29 factors and characterized by sex- and ancestry-specific patterns.<sup>8-11</sup> Dietary intake,  
30 socioeconomic status, physical inactivity, cigarette smoking, and alcohol consumption are  
31 common environmental factors that influence FA levels.<sup>12</sup> Although hundreds of genetic loci  
32 associated with FAs have been identified by genome-wide association studies (GWAS),<sup>13-38</sup> the  
33 biological mechanisms of these genetic associations remain largely unexplored. Moreover, these  
34 genetic loci were mainly discovered in the European (EUR) population and were focused on  
35 autosomes. Extending GWAS to non-EUR populations and sex chromosomes will offer a  
36 comprehensive understanding of the genetic architecture of circulating FAs.

37 In this study, we perform the GWAS for 19 FA traits related to PUFAs, MUFAs, and  
38 SFAs to identify more novel genetic loci. We conducted overall and sex-specific GWAS using  
39 250,101 individuals of EUR ancestry and five other ancestries from the UK Biobank (UKB).  
40 Leveraging the GWAS summary statistics, we characterized heritability for these FA traits and  
41 examined their shared genetic basis with genetic correlation and colocalization analysis.  
42 Candidate causal variants were pinpointed with statistical fine-mapping. Finally, we integrated  
43 GWAS signals with multi-omics data to identify the mediating molecular phenotypes and  
44 provide mechanistic insights into the molecular mechanisms underlying the GWAS signals.

## 45 **Methods**

### 46 **Participants**

47 The UKB cohort is a prospective population-based study of ~500,000 participants from  
48 across the United Kingdom, aged between 37 and 73 years at recruitment from 2006 to 2010.<sup>39</sup>  
49 Of the participants with both phenotype and genotype data, we excluded those who have  
50 withdrawn consent, mismatched information between self-reported and genetic sex, sex  
51 chromosome aneuploidy, or are outliers for heterogeneity and missing genotype rate. Genetic  
52 ancestry groups have been previously defined in the Pan-ancestry genetic analysis of the UK  
53 Biobank (Pan-UKB).<sup>40</sup> Together, we included up to 239,268 participants of EUR ancestry in this  
54 study. We also included participants of African (AFR) (N=3,352), admixed American (AMR)  
55 (N=508), Central/South Asian (CSA) (N=4,663), East Asian (EAS) (N=1,445), and  
56 Middle Eastern (MID) (N=865) ancestries. Table S1 provides the overall and sex-stratified  
57 characteristics of participants in each ancestry group. This study received ethical approval from  
58 the National Health Service North West Centre for Research Ethics Committee, and all  
59 participants provided informed consent. Data from the UKB resource were accessed under  
60 application number 48818.

### 61 **Phenotypes – circulating FAs**

62 Plasma FAs were measured in a randomly selected subset of 274,020 participants by  
63 Nightingale Health using nuclear magnetic resonance (NMR) spectroscopy.<sup>41</sup> All FA levels and  
64 their ratios were normalized within each ancestry group using the rank-based inverse normal  
65 transformation in overall GWAS.<sup>42</sup> This inverse normal transformation was applied separately  
66 for males and females to account for sex-specific differences in FA distributions. In total, 20  
67 metabolic measurements were initially analyzed in the GWAS, including total FAs, 5 PUFA

68 absolute concentrations (i.e., total PUFAs, omega-3 PUFAs, omega-6 PUFAs, docosahexaenoic  
69 acid (DHA), and linoleic acid (LA)), their relative percentages in total FAs (i.e., PUFAs%,  
70 omega-3%, omega-6%, DHA%, and LA%), the ratio of omega-3 to omega-6 PUFAs (omega-  
71 3/omega-6), the ratio of omega-6 to omega-3 PUFAs (omega-6/omega-3), monounsaturated fatty  
72 acids (MUFAs), saturated fatty acids (SFAs), MUFAs%, SFAs%, PUFAs/MUFAs,  
73 PUFAs/SFAs, and degree of unsaturation. Both the omega-3/omega-6 ratio and omega-6/omega-  
74 3 ratio were included in our GWAS due to different preferences in the field, but they revealed the  
75 same genetic loci in opposite effect directions. In additional analyses, we focused on omega-  
76 3/omega-6 and did not include omega-6/omega-3, resulting in a total of 19 plasma metabolic  
77 measurements. FA traits were categorized into PUFA-related traits (total PUFAs, omega-3  
78 PUFAs, omega-6 PUFAs, DHA, LA, PUFAs%, omega-3%, omega-6%, DHA%, LA%, omega-  
79 3/omega-6, PUFAs/MUFAs, PUFAs/SFAs, and degree of unsaturation), MUFA-related traits  
80 (total MUFAs, MUFAs%, and PUFAs/MUFAs), and SFA-related traits (total SFAs, SFAs%, and  
81 PUFAs/SFAs).

## 82 **Genotyping and quality control**

83 Full details about genotyping, imputation, and genotype-based quality control (QC) have  
84 been described elsewhere.<sup>43</sup> Briefly, we excluded variants with imputation quality score < 0.3,  
85 minor allele frequency < 0.001, genotype missingness per variant > 0.05, and Hardy-Weinberg  
86 test  $P$ -value <  $1 \times 10^{-8}$ . We also confirmed that no individuals have genotype missingness > 0.05.  
87 For the non-pseudoautosomal region of the X chromosome (GRCh37; chrX:2699520-  
88 154931044), males were treated as homozygotes of the reference or effect allele, and coded as 0  
89 or 2, respectively.

## 90 **Genome-wide association studies (GWAS)**

91 Overall GWAS were conducted for each ancestry group and followed by sex-stratified  
92 GWAS. We carried out GWAS in participants of EUR ancestry using fastGWA from the GCTA  
93 toolbox (v.1.94.1), which controls for familial relatedness using a sparse genetic relationship  
94 matrix (GRM) with a default threshold of 0.05 based on slightly linkage disequilibrium (LD)-  
95 pruned HapMap3 variants.<sup>44,45</sup> Considering the relatively small sample size for other ancestry  
96 groups (AFR, AMR, CSA, EAS, and MID), the mixed-linear-model association (MLMA)  
97 method was used to perform GWAS using the full GRM.<sup>46</sup> Additionally, sex-specific GWAS  
98 were conducted for each ancestry group using fastGWA for EUR participants and MLMA for  
99 other ancestry groups, excluding sex as a covariate from all models.

100 To explore the influences of potential covariates, we performed GWAS in the EUR  
101 ancestry participants using three models. In model 1, we included age, sex, age  $\times$  sex, and the top  
102 10 genetic principal components derived from the Pan-UKB as covariates. Model 2 added  
103 additional covariates, including body mass index, Townsend deprivation index, smoking status,  
104 alcohol status, physical activity, and statin use.<sup>47,48</sup> In model 3, we adjusted for fish oil  
105 supplementation status and lipoprotein lipids including chylomicron, very-low-density  
106 lipoprotein (VLDL), intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL),  
107 high-density lipoprotein (HDL) cholesterol as additional covariates. For GWAS in the non-EUR  
108 population, we applied models 1 and 2.

### 109 **Identification of novel loci**

110 To identify novel loci, we compared our independent loci to the previously reported FA  
111 loci in the GWAS Catalog and in other relevant publications identified by literature review up  
112 until June 2024.<sup>49</sup> Independent loci were identified in our results or previous GWAS based on  
113 genome-wide significance threshold ( $P$ -value  $< 5 \times 10^{-8}$ ) and LD-based clumping ( $r^2 = 0.1$ ,

114 window size = 250 kb) using PLINK.<sup>50,51</sup> Independent loci were merged based on proximity  
115 ( $\pm 250$  kb). We annotated the lead variants for their target genes and functional consequences  
116 using the Ensemble GRCh37 Variant Effect Predictor (VEP).<sup>52</sup>

### 117 **Heritability and genetic correlation analyses**

118 Heritability and genetic correlations were estimated with linkage disequilibrium score  
119 regression (LDSC) in the EUR ancestry subset.<sup>53,54</sup> In-sample LD scores were derived from  
120 [s3://broad-alkesgroup-ukbb-ld/UKBB\\_LD/](https://broad-alkesgroup-ukbb-ld/UKBB_LD/).<sup>55</sup> As recommended, we checked for inflation using  
121 the attenuation ratio in the EUR population and genomic inflation factor ( $\lambda_{GC}$ ) in other  
122 populations.<sup>56</sup>

### 123 **Colocalization with FA traits**

124 We performed colocalization analysis with HyPrColoc (v.1.0) to assess whether two or  
125 more FA traits share a putative causal variant.<sup>57</sup> Pairwise and multi-trait colocalization analyses  
126 were conducted for each pair or all FA traits altogether. We used the default priors, including the  
127 probability of a variant being associated with a single trait ( $\text{prior.l} = 1 \times 10^{-4}$ ) and the  
128 conditional probability of association with an additional trait ( $\text{prior.c} = 0.02$ ). A posterior  
129 probability (PP)  $> 0.8$  was considered as evidence for a shared causal variant.

### 130 **Statistical fine-mapping of GWAS loci**

131 To statistically fine-map the candidate causal variants for genome-wide significant loci  
132 associated with each FA trait, we used SuSiE (v.0.12.27).<sup>58</sup> The analysis was performed for the  
133 1 Mb region surrounding the lead variant of each genetic locus. We utilized in-sample LD  
134 information to estimate the correlations among SNPs. The 95% credible set identified potential  
135 causal variants based on their PP. Only variants with a PP  $> 0.8$  were reported, with higher PP  
136 values indicating more likely to be causal variants.

## 137 **Gene-based and gene-set analyses**

138 MAGMA v.1.08, implemented in FUMA, was used to perform gene-based and gene-set  
139 analyses.<sup>59,60</sup> In the gene-based analysis, a total of 19,665 protein-coding genes was tested, and  
140 Bonferroni correction was applied to establish the significance threshold ( $P \leq 0.05/19,665$   
141  $= 2.54 \times 10^{-6}$ ). We determined the enrichment of candidate FAs-associated genes in specific  
142 biological pathways, cellular components, or molecular functions. A total of 15,481 gene sets  
143 (5,497 curated gene sets and 9,984 gene ontology terms) obtained from MsigDB were tested,  
144 with the Bonferroni-corrected significance threshold set at  $P < 3.23 \times 10^{-6}$ .<sup>61</sup>

## 145 **Omics PIEiotRopic Association (OPERA) analysis**

146 To provide mechanistic interpretations of FAs-associated variants, we performed an  
147 integrative analysis of six types of multi-omics quantitative trait loci (QTL) summary statistics  
148 with GWAS signals using the Bayesian method, Omics PIEiotRopic Association (OPERA).<sup>62</sup>  
149 First, we obtained available molecular quantitative trait loci (xQTL) data, including gene  
150 expression QTL (eQTL), protein QTL (pQTL), DNA methylation QTL (mQTL), splicing QTL  
151 (sQTL), histone modification QTL (hQTL), and chromatin accessibility QTL (caQTL). We  
152 downloaded blood *cis*-eQTLs summary statistics generated from the eQTLGen study ( $N =$   
153  $31,684$ ).<sup>63</sup> The plasma pQTL summary statistics were retrieved from the UKB Pharma  
154 Proteomics Project (UKB-PPP) using UKB participants ( $N = 54,219$ ).<sup>64</sup> The peripheral blood  
155 mQTL data were generated by McRae *et al.* ( $N = 1,980$ ).<sup>65,66</sup> We derived summary-level sQTL  
156 data from whole blood samples in the Genotype Tissue Expression (GTEx) Project v.8 ( $N =$   
157  $670$ ).<sup>67</sup> The H3K27ac and H3K4me1 hQTL in monocytes were generated from the BLUEPRINT  
158 project ( $N = 200$ ).<sup>68</sup> The caQTL data in lymphoblastoid cell line samples were estimated by  
159 Kumasaka *et al.* ( $N = 100$ ).<sup>69</sup> We included the molecular phenotypes with at least one xQTL



160 with  $P < 5 \times 10^{-8}$  and excluded the major histocompatibility complex (MHC) region due to its  
161 structural complexity. After filtering molecular phenotypes, we retained 15,785 genes, 2,190  
162 proteins, 94,338 DNA methylation sites, 6,639 RNA splicing events, 18,152 histone marks, and  
163 13,873 chromatin accessibility peaks. The posterior probability of association (PPA) threshold of  
164 0.9 and the multi-exposure heterogeneity in dependent instruments (HEIDI) test threshold of  
165 0.01 were used to determine if a GWAS signal overlaps with the QTL signals for one or multiple  
166 molecular phenotypes.

## 167 **Results**

### 168 **Sample characteristics**

169 The primary GWAS comprised up to 239,268 individuals of EUR ancestry. GWAS were  
170 also conducted on five additional ancestry groups, including up to 3,352 AFR, 508 AMR, 4,663  
171 CSA, 1,445 EAS, and 865 MID individuals. Among EUR participants, the average age was 57  
172 years and females were more likely to have higher PUFA levels (Table S1). The percentage of  
173 female participants in EUR, AFR, AMR, CSA, EAS, and MID populations was 53.9%, 59.7%,  
174 66.9%, 44.8%, 64.6%, and 41.8%, respectively. Approximately 31.6% of individuals reported  
175 regular use of fish oil supplements and the ratio of omega-3/omega-6 was around 1:8.

### 176 **Identification of genome-wide significant loci for circulating FA traits**

177 We first performed EUR ancestry GWAS for each FA trait using three models,  
178 respectively. Overall, we identified between 37 and 124 loci for 19 FA traits in model 2, and  
179 between 26 and 48 loci in model 3 (Table S2). Approximately 13% of the loci (ranging from 0–  
180 22%) identified in model 2 were not significant in model 1 (Table S3). However, on average, 62%  
181 of the loci (range: 19–79%) from model 2 were not significant in model 3, and 31% (range: 18–  
182 43%) of the loci from model 3 were not identified in model 2 (Table S3). Figure 1A shows an  
183 example of the Manhattan plot of GWAS for the absolute concentration of total PUFAs in model  
184 2. Of the 122 significant loci identified in model 2, 30 for total PUFAs were also significant in  
185 model 3 and a total of 92 loci identified in model 2 were no longer significant after adjusting for  
186 fish oil intake and lipoprotein lipids in model 3 (Figure 1B). We observed similar effect  
187 estimates between models 1 and 2, whereas model 3 yielded systematically smaller effect  
188 estimates than those from the other two models (Figure S1). To further pinpoint the covariates  
189 driving the distinction between models 3 and 2, we conducted GWAS based on model 2 by

190 additionally adjusting for fish oil supplementation in model 2.1 and for lipoprotein lipids in  
191 model 2.2. The differences in GWAS results between model 3 and the others were attributed to  
192 the additional adjustment for lipoprotein lipids (Table S2). For example, variants in the *LDLR*  
193 and *MTTP* genes, known for their strong correlations with lipoprotein lipids,<sup>70,71</sup> were significant  
194 in model 2 but not in model 3 for total PUFAs (Figure 1).

195       Regarding SNP-based heritability of FA traits in the EUR population, we found that  
196 SNPs explained 5–19% of the phenotypic variance for all FA traits across all three models  
197 (Figure S2A; Table S4). For instance, the SNP-based heritability estimates for the absolute  
198 concentrations of total PUFAs, MUFAs, and SFAs were 19%, 19%, and 16%, respectively, in  
199 model 2. The genomic inflation factor ( $\lambda_{GC}$ ) for all GWAS ranged from 1.07 to 1.29 (Table S5).  
200 The attenuation ratio ranged from 0.03 to 0.18, and the LDSC intercept ranged from 1.01 to 1.12,  
201 suggesting that the genome-wide elevation of association statistics was primarily due to true  
202 additive polygenic effects rather than confounders such as population stratification.

203       To identify novel loci, we searched the literature and GWAS Catalog to compile known  
204 loci for FAs-related traits, making it the most comprehensive collection to date (Table S6). When  
205 categorizing FA traits into PUFAs-related, MUFAs-related, and SFAs-related, we identified 70,  
206 61, and 54 novel loci among 215, 163, and 119 significant loci, respectively, with model 2  
207 (Table S7). The numbers of novel loci for each FA trait are provided in Table S3. Compared  
208 with all previously reported FAs-related loci, the top 10 strongest novel loci identified across all  
209 FA traits in model 2 were mapped to candidate genes including *PEPD*, *SBNO1*, *IL1RN*, *INSIG2*,  
210 *VIM*, *PGS1*, *ARID5B*, *NF1*, *FAM96A*, and *PEX6* (Table S8). We also compared independent loci  
211 to those previously reported in GWAS for the same traits to identify loci that have not been  
212 previously associated with the corresponding trait. For example, a novel locus around *VEGFA*

213 was identified for total FAs, LA%, total SFAs, PUFAs/SFAs, and the degree of unsaturation in  
214 our study, while it was consistently associated with total MUFAs, MUFAs%, and  
215 PUFAs/MUFAs in both our and previous GWAS.<sup>30,33,34,38</sup> Variants in *GCKR* were found to be  
216 significantly associated with DHA% for the first time, while they had been associated with other  
217 FA traits (Table S8).

218 Additionally, we explored genetic associations on the X-chromosome in both overall and  
219 sex-specific GWAS. Previously, only one GWAS identified FA loci on the X-chromosome.<sup>30</sup>  
220 That GWAS reported two X-chromosomal loci associated with FA traits; however, no significant  
221 variants were identified in our overall GWAS. When evaluating males separately, one significant  
222 association with omega-3% was found on the X-chromosome.

### 223 **Sex-specific FA GWAS**

224 We then stratified the total sample by sex to perform sex-specific GWAS separately for  
225 128,922 females and 110,346 males in the EUR population. Approximately 4.2% of the  
226 significant loci from sex-specific GWAS were not identified in the overall GWAS (Table S3).  
227 The SNP-based heritability ranged from 5% to 21% in females and 4% to 20% in males, and  
228 there was no evidence of genomic inflation (Figures S2B and S2C; Table S4). In model 2, we  
229 identified 128 independent loci associated with PUFAs-related traits in females and 106 loci in  
230 males, including 27 and 8 novel loci, respectively, which have not been reported in previous  
231 GWAS of PUFAs-related traits (Table S7). GWAS results for both known and novel loci  
232 associated with each FA trait are provided in Table S9 for females and Table S10 for males.  
233 Some novel loci were only identified in one sex but not in the other. For example, in the model 2  
234 GWAS for total PUFAs, there were three novel loci in females but not in males, when compared  
235 to previous GWAS of all FA traits. Two of them were mapped to genes *RNU6-1180P* and

236 *KRT18P55*, while the third locus, located on Chromosome 10, was not mapped to any genes  
237 (Figure 2). Similarly, in the model 3 GWAS for total PUFAs, there were three novel loci, around  
238 genes *UNC5CL*, *RP11-328J6.1*, and *SIPA1L3*, which were identified only in females (Figure S3).  
239 No novel loci were identified in male-specific GWAS for total PUFAs in either model 2 or 3. In  
240 the sex-specific GWAS, we found that approximately 43% of the genome-wide significant loci  
241 identified in models 1 and 2 were not identified in model 3 (Table S3). On the other hand, about  
242 31% of the loci identified in model 3 were not identified in the other two models (Table S3).  
243 Notably, one X-chromosomal locus associated with omega-3%, whose lead SNP is rs147828433,  
244 was identified from GWAS using model 2 in males. Our study is the first to explore loci in sex-  
245 specific GWAS of FA traits and to include the X chromosome.

#### 246 **GWAS for FA traits in individuals of non-EUR ancestries**

247 Across all FA traits, we identified 38 significant loci in ancestry-specific GWAS, of  
248 which 23 are novel compared to previous studies in EUR and non-EUR populations (Table S11).  
249 The genomic inflation factor ( $\lambda_{GC}$ ) was also reported for each non-EUR ancestry, with average  
250  $\lambda_{GC}$  values of 0.97, 0.92, 0.99, 0.90, and 0.95 for AFR, AMR, CSA, EAS, and MID, respectively  
251 (Tables S5). In the non-EUR ancestry GWAS, the most significant locus was around *FADS2*,  
252 identified in four ancestry groups except AFR, which is a well-known locus in the EUR  
253 population (Table S11). Among non-EUR populations, CSA had the largest sample size, leading  
254 to more loci being identified compared to other groups, with 1–4 loci in model 1 and 0–2 in  
255 model 2 (Table S2). The GWAS in CSA male participants identified a novel locus *EDNI*  
256 associated with total PUFAs, omega-6 PUFAs, and LA, while this locus did not reach the  
257 genome-wide significance in the EUR population. In addition, variants in *VPS39*, which had not

258 been reported in previous GWAS, were associated with total PUFAs, omega-6 PUFAs, and LA  
259 in both total and male-only CSA participants.

### 260 **Genetic correlations among FA traits**

261 We examined genetic correlations ( $r_g$ ) between FA traits using EUR GWAS summary  
262 statistics from three models (Table S12). Broadly, comparisons of genetic correlations between  
263 models revealed highly consistent estimates between models 1 and 2 but more distinct estimates  
264 in model 3 (Figure S4). Among the 171 pairs of genetic correlations, 14 pairs that had  
265 significantly negative genetic correlations in models 1 and 2 became significantly positive in  
266 model 3, while four pairs that were significantly positive in models 1 and 2 became significantly  
267 negative in model 3. The strongest correlation was a negative correlation between total MUFAs  
268 and PUFAs/MUFAs ( $r_g = -0.99$ ) observed based on GWAS in both models 1 and 2 (Figures S5  
269 and S6). Notably, genetic correlations between omega-6 PUFAs and omega-6% were negative in  
270 models 1 ( $r_g = -0.38$ ) and 2 ( $r_g = -0.51$ ), but they were positively correlated in model 3 ( $r_g =$   
271  $0.34$ ) after further adjustment for lipoprotein lipids (Figure S7). Within omega-3-related traits,  
272 genetic correlations were strong ( $\sim 0.9$ ) across all three models, with even stronger correlations  
273 found in model 3. We also estimated pairwise phenotypic correlations using Pearson's  
274 correlation coefficient (Table S13). Among significant genetic correlations, all pairs had  
275 consistent directions compared to phenotypic correlations in models 1 and 2, while 83% of pairs  
276 had consistent directions in model 3, suggesting that genetic effects on FA traits were altered  
277 after adding lipoprotein lipids as covariates.

### 278 **Colocalization of GWAS signals across FA traits**

279 To assess the probability that two FA traits share the same causal variants, we conducted  
280 pairwise colocalization analyses. For the 171 pairs of FA traits, we identified 9–231 colocalized

281 signals in model 2 and 6–114 signals in model 3, respectively. We found that pairs with a larger  
282 number of colocalized signals also had stronger genetic correlations (Figure S8). In model 2,  
283 potential causal variants in *DOCK7* (rs2934744), *GCKR* (rs1260326), *ZNF259* (rs964184),  
284 *FADS1* (rs174564), *CPT1A* (rs2229738), *LIPC* (rs2070895), *LIPG* (rs77960347), *LDLR*  
285 (rs73015024), *TM6SF2* (rs58542926), and *APOE* (rs7412) showed robust evidence of  
286 colocalization, indicating shared genetic variants for pairs of FA traits (Table S14). After  
287 accounting for lipoprotein lipids in model 3, *FADS1* (rs174564), *CPT1A* (rs2229738), and  
288 *BUDI3* (chr11:116623213:TA:T) were identified as colocalized for FA traits, consistent with  
289 results from model 2 (Table S15). Next, we performed multi-trait colocalization analyses to  
290 evaluate the posterior probability of a shared genetic signal across all FA traits. Overall, 168 and  
291 159 colocalized signals were identified in models 2 and 3, respectively. We identified *GCKR*  
292 (rs1260326), *TRIB1* (rs28601761), *FADS1* (rs174564), *ZNF259* (rs964184), and *APOE* (rs7412)  
293 as shared among multiple FA traits in model 2 (Table S16), and *GCKR* (rs1260326), *TRIB1*  
294 (rs28601761), *FADS1* (rs174564), and *APOE* (rs1065853) from model 3 as shared signals (Table  
295 S17).

## 296 **Statistical fine-mapping for candidate causal variants**

297 We applied the Bayesian fine-mapping method to identify putative causal variants for FA  
298 traits. We identified 477 unique potential causal variants in model 1, 422 in model 2, and 193 in  
299 model 3 (Table S18). Consistent with colocalization analysis, we confirmed that the genetic  
300 variants at the loci *TRIB1* (rs28601761), *FADS1* (rs174564), *CPT1A* (rs2229738), *LIPC*  
301 (rs2070895), *LIPG* (rs77960347), *LDLR* (rs72658867), *TM6SF2* (rs58542926), and *APOE*  
302 (rs7412) are likely to be causally associated with FA traits. Notably, we found that several loci  
303 contain multiple 95% credible sets, indicating the existence of multiple potential causal variants

304 within those significant loci. Among the novel loci for FA traits, we found that *ZMIZ1*  
305 (rs1782652) was associated with total FAs, total PUFAs, and omega-3 PUFAs, suggesting that it  
306 is a candidate shared causal variant for these FAs. Additional potential causal variants for novel  
307 loci were identified, including *CPS1* (rs1047891), *ATXN7L1* (rs118061830), *ARID5B*  
308 (rs77044968), *SBF2* (rs12789941), *DGKZ* (rs149903077), *CYFIP1* (rs199854211), *FAM96A*  
309 (rs62023393), *MIR122* (rs41292412), *BCL2* (rs12454712), *INSR* (rs112630404), and *PEPD*  
310 (rs62102718).

### 311 **Gene-based and gene-set enrichment analyses**

312 In the genome-wide gene-based association study, 139–541 genes from model 2 and  
313 110–255 genes from model 3 were found to be significantly associated with 19 FA traits after  
314 Bonferroni correction (Table S19). The top gene across 19 FA traits identified in model 2 was  
315 *ALDH1A2* (chr15:58245622-58790065), which overlaps with another identified gene *LIPC*  
316 (chr15:58702768-58861151). In the GWAS of the omega-3/omega-6 ratio using model 3, *STH*  
317 was the top gene, which might be related to neurodegenerative diseases such as Alzheimer's  
318 disease.<sup>72</sup> Gene-tissue expression analysis revealed that the liver was the most significantly  
319 enriched tissue, followed by whole blood, kidney, small intestine, spleen, nerve, and adipose  
320 tissue (Tables S20 and 21). Additionally, gene-set enrichment analyses were performed to  
321 investigate potential gene sets and pathways with enriched GWAS signals (Tables S22 and 23).  
322 We found that genes associated with total PUFAs tend to be enriched in biological processes  
323 related to lipid homeostasis, secondary alcohol metabolism, organic hydroxy compound transport,  
324 regulations of plasma lipoprotein particle levels and lipid metabolism, and fatty acid biosynthesis  
325 (Figure 3). Fatty acid metabolic and biosynthetic processes were significantly enriched in the  
326 gene-set analysis results from GWAS of total PUFAs using model 3 (Figure S9).



## 327 **OPERA identifies intermediate molecular phenotypes underlying FAs-associated loci**

328 To better understand the biological mechanisms of our GWAS findings, we applied  
329 OPERA to explore the overlap of GWAS signals for FA traits and QTL signals for six molecular  
330 phenotypes, including eQTL, pQTL, mQTL, sQTL, hQTL, and caQTL. With a PPA threshold of  
331 0.9 and a  $P_{\text{HEIDI}}$  threshold of 0.01, we identified 976 FAs-associated variants that overlapped  
332 with QTL signals for 2,106 unique molecular phenotype measures, including the expression  
333 levels of 242 genes, the abundance levels of 60 proteins, the methylation levels at 1,254 DNA  
334 sites, the RNA splicing events at 141 sites, the status of 233 histone marks, and the openness at  
335 176 chromatin accessibility peaks (Figure 4A; Table S24). After adjusting for lipoprotein lipids  
336 in model 3, we found 481 variants overlapping with xQTLs (Figure 4B; Table S25). Associations  
337 with DNA methylation were more frequent than with other molecular phenotypes, and these  
338 findings were consistent with previous results in other complex traits.<sup>62</sup> The number of loci  
339 associated with eQTL across 19 traits ranged from 7 for the degree of unsaturation to 68 for total  
340 PUFAs in model 2, and from 2 to 41 in model 3. Using the pQTL data from UKB-PPP, we  
341 observed that omega-3 PUFAs had the highest number of significant associations with proteins,  
342 identifying 35 loci in model 2 and 36 loci in model 3.

343 We found that approximately 65% of GWAS loci for 19 FA traits were shared with at  
344 least one molecular phenotype. Across FA traits such as total FAs, total PUFAs, omega-6  
345 PUFAs, and total SFAs, the potential causal variant rs72658867, annotated at the *LDLR* gene,  
346 was associated with histone modification (chr19:11105519-11214483) and chromatin  
347 accessibility (peak 264429). Among the novel loci for omega-6%, rs149903077 (*DGKZ*) was  
348 jointly associated with the expression of nearby gene *NR1H3* (ENSG00000025434), histone

349 modification (chr11:47234446-47272168), and chromatin accessibility (peak 200213). It was  
350 also marginally associated with methylation (cg01183595).

351 Notably, all six molecular phenotypes had colocalized QTL signals with omega-6%, total  
352 FAs, and total MUFAs at the novel locus *GSTTP1* or nearby genes on chromosome 22 (Figure 5).  
353 We observed that the gene *EML3* was associated with the omega-3/omega-6 ratio jointly with  
354 five other types of molecular phenotypes, except for histone modification (Figure S10). The  
355 nearby variants rs12786457 and rs184864731 were consistently associated with these five  
356 phenotypes across GWAS related to omega-3 PUFAs and omega-3%. Overall, OPERA  
357 integrates six types of xQTL data to offer mechanistic insights into genetic loci and their  
358 downstream molecular phenotypes.

## 359 Discussion

360 We performed overall and sex-specific GWAS for 19 FA traits in 250,101 UKB  
361 participants of EUR descent and five other ancestry groups, separately. We identified 215, 163,  
362 and 119 significant loci for PUFAs-, MUFAs-, and SFAs-related traits, including 70, 61, and 54  
363 novel loci, respectively, in our primary model (i.e., model 2). Further adjustment for lipoprotein  
364 lipids in model 3 resulted in significant changes in GWAS signals. On average, 62% of the loci  
365 (range: 19–79%) from model 2 were not significant in model 3, while 31% (range: 18–43%) of  
366 the loci from model 3 were not identified in model 2. Our analyses of genetic correlations and  
367 colocalization revealed the levels of shared genetic basis and specific candidate shared variants  
368 across FA traits. Using statistical fine-mapping, we identified 422 putative causal variants across  
369 all FA traits. Gene-based and gene-set enrichment analyses pinpointed the liver as the most  
370 relevant tissue and highlighted biological pathways underlying FA loci. In addition, we  
371 integrated GWAS signals with QTL signals for six molecular phenotypes and revealed that  
372 approximately 65% of GWAS loci for 19 FA traits were shared with at least one molecular  
373 phenotype, offering novel mechanistic insights.

374 In EUR GWAS, we analyzed 19 plasma NMR measures of FAs in UKB 239,268  
375 participants. Although previous GWAS of FA traits in the UKB reported many loci, we  
376 identified approximately 90% more loci with a doubled sample size.<sup>30,33,34</sup> In addition, we  
377 compared our results with all previous GWAS of FAs-related traits to identify novel loci,  
378 including the second-largest published GWAS to date, which included 136,016 participants from  
379 33 cohorts.<sup>38</sup> We calculated the omega-3/omega-6 and PUFA/SFA ratios for GWAS for the first  
380 time. Although the omega-6 to omega-3 ratio is commonly used in studies, the omega-3/omega-6  
381 ratio may better capture the benefits of omega-3. This is particularly relevant given the ongoing

382 debate over the potential harmful or beneficial effects of omega-6 PUFAs.<sup>73</sup> Our large GWAS of  
383 FAs showed that the phenotypic variance explained by all SNPs ranged from 5–19%, while  
384 heritability estimates from twin studies were approximately 25–62%.<sup>15</sup> These results suggest that  
385 future studies with rare or structural variants from sequencing and more diverse ancestry groups  
386 could be valuable for identifying additional loci for FA traits.

387 Integrating comprehensive multi-omics data facilitates understanding the mechanisms  
388 behind genetic loci and their downstream molecular phenotypes. Our study shows over half of  
389 GWAS loci (~65%) for 19 FA traits are associated with at least one molecular phenotype. For  
390 example, the *LDLR* gene variant rs72658867 is linked to histone modification  
391 (19:11105519:11214483) and chromatin accessibility (264429), impacting lipid metabolism and  
392 cardiovascular health.<sup>74</sup> The variant rs149903077 in the novel *DGKZ* locus has been associated  
393 with the expression of nearby gene *NR1H3*, chromatin accessibility, histone modifications, and  
394 DNA methylation, highlighting their combined roles in nuclear receptor regulation, lipid  
395 metabolism, and immune responses.<sup>75</sup> The novel *GSTTP1* locus from the glutathione S-  
396 transferase (GST) family and nearby genes on chromosome 22 were identified for omega-6%,  
397 total FAs, and total MUFAs, overlapping with all six molecular phenotypes and have been linked  
398 to key biological processes such as detoxification, cancer susceptibility, and cellular responses to  
399 oxidative stress.<sup>76</sup> These genes in the GST family have previously been reported to be associated  
400 with prostate cancer risk, and a recent study found evidence of a nonlinear relationship between  
401 omega-6% and prostate cancer.<sup>77-80</sup> Future studies are needed to validate our findings on the  
402 molecular mechanisms underlying FA-relevant variants. These insights could aid in patient  
403 stratification for precision nutrition and in identifying novel therapeutic targets related to FAs.

404 Gene-set enrichment analysis findings highlight biological pathways underlying FA loci,  
405 implicating lipid homeostasis, transport, and metabolism, and providing genetic support for the  
406 current understanding of fatty acid regulation.<sup>81</sup> Our previous study suggested that lower omega-  
407 6% may reduce alcohol consumption, with the secondary alcohol metabolism pathway  
408 potentially explaining this effect on alcohol-related behaviors.<sup>6</sup> In model 3, which adjusts for  
409 lipoprotein lipid levels, fatty acid metabolic and biosynthetic processes were significantly more  
410 enriched in the gene-set analysis of GWAS of total PUFAs. The investigation of the disparities  
411 between models 2 and 3 suggests that lipoprotein-related biomarkers play a critical role in FA  
412 loci. Future studies are needed to thoroughly dissect these roles, and further analyses, such as  
413 Mendelian randomization, should properly infer results using genetic variants with or without  
414 adjustment for lipoprotein-related biomarkers.<sup>82</sup>

415 We investigated the sex-specific genetic architecture of FA traits. A novel locus,  
416 *KRT18P55*, was identified in the GWAS for females, and previous research indicates that this  
417 locus is highly expressed in patients with gastric cancer.<sup>83</sup> Notably, only one X-chromosomal  
418 locus was identified in the male-only GWAS for omega-3%, tagged by the lead variants  
419 rs147828433 (closest protein-coding gene: *ACOT9*). A study on *ACOT9* in mice suggests that it  
420 regulates both fatty acid and amino acid metabolism in mitochondria.<sup>84</sup> For the female-only  
421 GWAS, the heritability was higher, and larger numbers of loci were identified. Our results  
422 highlight the importance of tracking sex differences in genetics and may motivate future studies  
423 on gene-sex interactions. We found higher plasma PUFA levels in females, consistent with  
424 previous studies, which were influenced by genetic effects, sex hormones, and conversion rates  
425 in FA metabolism.<sup>9</sup> Randomized controlled trials show sex- and race-specific differences in the

426 benefits of fish oil supplementation and omega-3 PUFAs for preventing cardiovascular events  
427 and cognitive decline.<sup>85</sup>

428 By performing ancestry-specific and sex-specific GWAS in non-EUR samples, we  
429 identified additional novel loci, suggesting the presence of ancestry-specific genetic loci for FA  
430 traits. In male CSA participants, the novel locus *EDNI*, associated with omega-6 PUFA traits,  
431 encodes the protein endothelin 1, which has been linked to cardiovascular events and  
432 prognosis.<sup>86</sup> Variants in *VPS39*, associated with omega-6 PUFAs in the CSA population, have  
433 been previously identified as important regulators of myoblast differentiation and muscle glucose  
434 uptake in patients with type 2 diabetes.<sup>87</sup> Besides these ancestry-specific signals, we also found  
435 that several loci identified from large EUR GWAS were transferable to other ancestry groups,  
436 including *FADS2*, *ZNF259*, *MYRF*, *APOA5*, *GCKR*, *APOE*, and other loci. We found  
437 significantly fewer loci in the other five non-EUR ancestry GWAS due to small sample sizes.  
438 These results suggest that future studies with larger and more diverse ancestry samples are  
439 needed to identify more loci and confirm their consistency across populations.

440 To the best of our knowledge, our study is the most comprehensive GWAS on FA traits  
441 in a very large cohort. First, this is the first study to integrate six types of xQTL data with FA  
442 GWAS to explore the possible molecular mechanisms of FAs-associated genetic variants.  
443 Second, we used a large number of participants of EUR ancestry with plasma NMR measures for  
444 19 FA traits and included participants from five other ancestry groups. Third, the inclusion of the  
445 omega-3/omega-6 ratio in the GWAS provides better insights into the benefits of omega-3  
446 PUFAs. Fourth, our sex-specific GWAS on EUR and non-EUR populations, as well as the  
447 inclusion of X-chromosomal, uncover sex differences in FA genetic basis. Fifth, we  
448 comprehensively compared our findings to all previous GWAS of FAs-related traits. Detailed

449 information on all novel and known loci has been provided (Tables S3 and S6), which offers a  
450 valuable resource for the FA research community. Finally, we adjusted for various covariates  
451 across three models, with a particular focus on genetic architecture adjusted for lipoprotein  
452 metabolism.

453 The study has limitations. The numbers of participants in non-EUR populations were  
454 small, and future studies with larger sample sizes are necessary. While we explored the  
455 molecular mechanisms of FA loci, we are eager to extend OPERA analysis to other tissue-  
456 specific molecular phenotypes, particularly the liver, and even specific cell types, to identify cell  
457 type-specific disease mechanisms.

458 In conclusion, our findings reveal novel genetic loci and provide the first evidence of  
459 molecular mechanisms underlying FAs-relevant variants. These insights could aid population  
460 stratification for precision nutrition and the identification of novel therapeutic targets for FAs-  
461 related diseases.

## 462 **Data availability**

463 The full summary statistics for GWAS of fatty acids are publicly available in the GWAS Catalog  
464 database (<https://www.ebi.ac.uk/gwas/>, GCP ID: TBA after peer review). The blood eQTL data  
465 of eQTLGen Consortium used in the analyses were downloaded from  
466 [https://molgenis26.gcc.rug.nl/downloads/eqtlgen/cis-eqtl/SMR\\_formatted/cis-eQTL-](https://molgenis26.gcc.rug.nl/downloads/eqtlgen/cis-eqtl/SMR_formatted/cis-eQTL-)  
467 [https://zenodo.org/records/7951839/files/LBC\\_BSGS\\_meta.tar.gz?download=1SMR\\_20191212.](https://zenodo.org/records/7951839/files/LBC_BSGS_meta.tar.gz?download=1SMR_20191212)  
468 [tar.gz](https://zenodo.org/records/7951839/files/LBC_BSGS_meta.tar.gz?download=1). UKBB pQTL data are available at <https://metabolomics.org/ukbbpgwas/>. The mQTL data  
469 are available for download from  
470 [https://zenodo.org/records/7951839/files/LBC\\_BSGS\\_meta.tar.gz?download=1](https://zenodo.org/records/7951839/files/LBC_BSGS_meta.tar.gz?download=1). Blood sQTL  
471 data can be downloaded at  
472 [https://yanglab.westlake.edu.cn/data/SMR/GTEx\\_V8\\_cis\\_sqtl\\_summary/sQTL\\_Whole\\_Blood.zi](https://yanglab.westlake.edu.cn/data/SMR/GTEx_V8_cis_sqtl_summary/sQTL_Whole_Blood.zip)  
473 [p](https://yanglab.westlake.edu.cn/data/SMR/GTEx_V8_cis_sqtl_summary/sQTL_Whole_Blood.zip). The hQTL data can be assessed from  
474 [http://ftp.ebi.ac.uk/pub/databases/blueprint/blueprint\\_Epivar/ctl\\_as/QTL\\_RESULTS/](http://ftp.ebi.ac.uk/pub/databases/blueprint/blueprint_Epivar/ctl_as/QTL_RESULTS/). Summary  
475 statistics of caQTL can be found at <https://zenodo.org/records/1405945/files/>.

## 476 **Supplemental information**

477 Supplemental information can be found online at <https://doi.org/>.

## 478 **Acknowledgments**

479 This research was approved by the University of Georgia Institutional Review Board and the UK  
480 Biobank consortium (application no. 48818). This work was funded by the University of Georgia  
481 Research Foundation and by the National Institute of General Medical Sciences of the National  
482 Institutes of Health under Award Number R35GM143060. The content is solely the  
483 responsibility of the authors and does not necessarily represent the official views of the National  
484 Institutes of Health.



485 **Author contributions**

486 Y.S. and K.Y. designed the study. Y.S. and H.X. performed analyses. Y.S. and K.Y. drafted the

487 manuscript. All authors contributed to the review and critical revision of the manuscript.

488 **Declaration of interests**

489 The authors declare no competing interests.

## References

- 490 1. Worthmann, A., Ridder, J., Piel, S.Y.L., Evangelakos, I., Musfeldt, M., Voss, H., O'Farrell,  
491 M., Fischer, A.W., Adak, S., Sundd, M., et al. (2024). Fatty acid synthesis suppresses  
492 dietary polyunsaturated fatty acid use. *Nat Commun* 15, 45. [10.1038/s41467-023-](https://doi.org/10.1038/s41467-023-44364-y)  
493 [44364-y](https://doi.org/10.1038/s41467-023-44364-y).
- 494 2. Baum, S.J., Kris-Etherton, P.M., Willett, W.C., Lichtenstein, A.H., Rudel, L.L., Maki, K.C.,  
495 Whelan, J., Ramsden, C.E., and Block, R.C. (2012). Fatty acids in cardiovascular health  
496 and disease: a comprehensive update. *J Clin Lipidol* 6, 216-234.  
497 [10.1016/j.jacl.2012.04.077](https://doi.org/10.1016/j.jacl.2012.04.077).
- 498 3. Astrup, A., Magkos, F., Bier, D.M., Brenna, J.T., de Oliveira Otto, M.C., Hill, J.O., King, J.C.,  
499 Mente, A., Ordovas, J.M., Volek, J.S., et al. (2020). Saturated Fats and Health: A  
500 Reassessment and Proposal for Food-Based Recommendations: JACC State-of-the-Art  
501 Review. *J Am Coll Cardiol* 76, 844-857. [10.1016/j.jacc.2020.05.077](https://doi.org/10.1016/j.jacc.2020.05.077).
- 502 4. Scorletti, E., and Byrne, C.D. (2013). Omega-3 fatty acids, hepatic lipid metabolism, and  
503 nonalcoholic fatty liver disease. *Annu Rev Nutr* 33, 231-248. [10.1146/annurev-nutr-](https://doi.org/10.1146/annurev-nutr-071812-161230)  
504 [071812-161230](https://doi.org/10.1146/annurev-nutr-071812-161230).
- 505 5. Zhang, Y., Sun, Y., Yu, Q., Song, S., Brenna, J.T., Shen, Y., and Ye, K. (2024). Higher ratio  
506 of plasma omega-6/omega-3 fatty acids is associated with greater risk of all-cause,  
507 cancer, and cardiovascular mortality: A population-based cohort study in UK Biobank.  
508 *Elife* 12. [10.7554/eLife.90132](https://doi.org/10.7554/eLife.90132).
- 509 6. Xu, H., Sun, Y., Francis, M., Cheng, C.F., Modulla, N.T.R., Brenna, J.T., Chiang, C.W.K., and  
510 Ye, K. (2023). Shared genetic basis informs the roles of polyunsaturated fatty acids in  
511 brain disorders. *medRxiv*. [10.1101/2023.10.03.23296500](https://doi.org/10.1101/2023.10.03.23296500).
- 512 7. Sun, Y., Chatterjee, R., Ronanki, A., and Ye, K. (2022). Circulating Polyunsaturated Fatty  
513 Acids and COVID-19: A Prospective Cohort Study and Mendelian Randomization Analysis.  
514 *Front Med (Lausanne)* 9, 923746. [10.3389/fmed.2022.923746](https://doi.org/10.3389/fmed.2022.923746).
- 515 8. Hodson, L., Skeaff, C.M., and Fielding, B.A. (2008). Fatty acid composition of adipose  
516 tissue and blood in humans and its use as a biomarker of dietary intake. *Prog Lipid Res*  
517 *47*, 348-380. [10.1016/j.plipres.2008.03.003](https://doi.org/10.1016/j.plipres.2008.03.003).
- 518 9. Decsi, T., and Kennedy, K. (2011). Sex-specific differences in essential fatty acid  
519 metabolism. *Am J Clin Nutr* 94, 1914S-1919S. [10.3945/ajcn.110.000893](https://doi.org/10.3945/ajcn.110.000893).
- 520 10. Mathias, R.A., Pani, V., and Chilton, F.H. (2014). Genetic Variants in the FADS Gene:  
521 Implications for Dietary Recommendations for Fatty Acid Intake. *Curr Nutr Rep* 3, 139-  
522 148. [10.1007/s13668-014-0079-1](https://doi.org/10.1007/s13668-014-0079-1).
- 523 11. Francis, M., Li, C., Sun, Y., Zhou, J., Li, X., Brenna, J.T., and Ye, K. (2021). Genome-wide  
524 association study of fish oil supplementation on lipid traits in 81,246 individuals reveals  
525 new gene-diet interaction loci. *PLoS Genet* 17, e1009431.  
526 [10.1371/journal.pgen.1009431](https://doi.org/10.1371/journal.pgen.1009431).
- 527 12. Zhuang, P., Liu, X., Li, Y., Wu, Y., Li, H., Wan, X., Zhang, L., Xu, C., Jiao, J., and Zhang, Y.  
528 (2023). Circulating fatty acids, genetic risk, and incident coronary artery disease: A  
529 prospective, longitudinal cohort study. *Sci Adv* 9, eadf9037. [10.1126/sciadv.adf9037](https://doi.org/10.1126/sciadv.adf9037).
- 530 13. Tanaka, T., Shen, J., Abecasis, G.R., Kislaliou, A., Ordovas, J.M., Guralnik, J.M., Singleton,  
531 A., Bandinelli, S., Cherubini, A., Arnett, D., et al. (2009). Genome-wide association study

- 532 of plasma polyunsaturated fatty acids in the InCHIANTI Study. *PLoS Genet* 5, e1000338.  
533 10.1371/journal.pgen.1000338.
- 534 14. Lemaitre, R.N., Tanaka, T., Tang, W., Manichaikul, A., Foy, M., Kabagambe, E.K.,  
535 Nettleton, J.A., King, I.B., Weng, L.C., Bhattacharya, S., et al. (2011). Genetic loci  
536 associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide  
537 association studies from the CHARGE Consortium. *PLoS Genet* 7, e1002193.  
538 10.1371/journal.pgen.1002193.
- 539 15. Kettunen, J., Tukiainen, T., Sarin, A.P., Ortega-Alonso, A., Tikkanen, E., Lytikainen, L.P.,  
540 Kangas, A.J., Soininen, P., Wurtz, P., Silander, K., et al. (2012). Genome-wide association  
541 study identifies multiple loci influencing human serum metabolite levels. *Nat Genet* 44,  
542 269-276. 10.1038/ng.1073.
- 543 16. Wu, J.H., Lemaitre, R.N., Manichaikul, A., Guan, W., Tanaka, T., Foy, M., Kabagambe, E.K.,  
544 Djousse, L., Siscovick, D., Fretts, A.M., et al. (2013). Genome-wide association study  
545 identifies novel loci associated with concentrations of four plasma phospholipid fatty  
546 acids in the de novo lipogenesis pathway: results from the Cohorts for Heart and Aging  
547 Research in Genomic Epidemiology (CHARGE) consortium. *Circ Cardiovasc Genet* 6, 171-  
548 183. 10.1161/CIRCGENETICS.112.964619.
- 549 17. Guan, W., Steffen, B.T., Lemaitre, R.N., Wu, J.H.Y., Tanaka, T., Manichaikul, A., Foy, M.,  
550 Rich, S.S., Wang, L., Nettleton, J.A., et al. (2014). Genome-wide association study of  
551 plasma N6 polyunsaturated fatty acids within the cohorts for heart and aging research in  
552 genomic epidemiology consortium. *Circ Cardiovasc Genet* 7, 321-331.  
553 10.1161/CIRCGENETICS.113.000208.
- 554 18. Lemaitre, R.N., King, I.B., Kabagambe, E.K., Wu, J.H., McKnight, B., Manichaikul, A., Guan,  
555 W., Sun, Q., Chasman, D.I., Foy, M., et al. (2015). Genetic loci associated with circulating  
556 levels of very long-chain saturated fatty acids. *J Lipid Res* 56, 176-184.  
557 10.1194/jlr.M052456.
- 558 19. Tintle, N.L., Pottala, J.V., Lacey, S., Ramachandran, V., Westra, J., Rogers, A., Clark, J.,  
559 Olthoff, B., Larson, M., Harris, W., and Shearer, G.C. (2015). A genome-wide association  
560 study of saturated, mono- and polyunsaturated red blood cell fatty acids in the  
561 Framingham Heart Offspring Study. *Prostaglandins Leukot Essent Fatty Acids* 94, 65-72.  
562 10.1016/j.plefa.2014.11.007.
- 563 20. Dorajoo, R., Sun, Y., Han, Y., Ke, T., Burger, A., Chang, X., Low, H.Q., Guan, W., Lemaitre,  
564 R.N., Khor, C.C., et al. (2015). A genome-wide association study of n-3 and n-6 plasma  
565 fatty acids in a Singaporean Chinese population. *Genes Nutr* 10, 53. 10.1007/s12263-  
566 015-0502-2.
- 567 21. Hu, Y., Li, H., Lu, L., Manichaikul, A., Zhu, J., Chen, Y.D., Sun, L., Liang, S., Siscovick, D.S.,  
568 Steffen, L.M., et al. (2016). Genome-wide meta-analyses identify novel loci associated  
569 with n-3 and n-6 polyunsaturated fatty acid levels in Chinese and European-ancestry  
570 populations. *Hum Mol Genet* 25, 1215-1224. 10.1093/hmg/ddw002.
- 571 22. Kettunen, J., Demirkan, A., Wurtz, P., Draisma, H.H., Haller, T., Rawal, R., Vaarhorst, A.,  
572 Kangas, A.J., Lytikainen, L.P., Pirinen, M., et al. (2016). Genome-wide study for  
573 circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. *Nat*  
574 *Commun* 7, 11122. 10.1038/ncomms11122.

- 575 23. Kalsbeek, A., Veenstra, J., Westra, J., Disselkoen, C., Koch, K., McKenzie, K.A., O'Bott, J.,  
576 Vander Woude, J., Fischer, K., Shearer, G.C., et al. (2018). A genome-wide association  
577 study of red-blood cell fatty acids and ratios incorporating dietary covariates:  
578 Framingham Heart Study Offspring Cohort. *PLoS One* *13*, e0194882.  
579 [10.1371/journal.pone.0194882](https://doi.org/10.1371/journal.pone.0194882).
- 580 24. de Oliveira Otto, M.C., Lemaitre, R.N., Sun, Q., King, I.B., Wu, J.H.Y., Manichaikul, A., Rich,  
581 S.S., Tsai, M.Y., Chen, Y.D., Fornage, M., et al. (2018). Genome-wide association meta-  
582 analysis of circulating odd-numbered chain saturated fatty acids: Results from the  
583 CHARGE Consortium. *PLoS One* *13*, e0196951. [10.1371/journal.pone.0196951](https://doi.org/10.1371/journal.pone.0196951).
- 584 25. Marklund, M., Morris, A.P., Mahajan, A., Ingelsson, E., Lindgren, C.M., Lind, L., and  
585 Riserus, U. (2018). Genome-Wide Association Studies of Estimated Fatty Acid  
586 Desaturase Activity in Serum and Adipose Tissue in Elderly Individuals: Associations with  
587 Insulin Sensitivity. *Nutrients* *10*. [10.3390/nu10111791](https://doi.org/10.3390/nu10111791).
- 588 26. Locke, A.E., Steinberg, K.M., Chiang, C.W.K., Service, S.K., Havulinna, A.S., Stell, L.,  
589 Pirinen, M., Abel, H.J., Chiang, C.C., Fulton, R.S., et al. (2019). Exome sequencing of  
590 Finnish isolates enhances rare-variant association power. *Nature* *572*, 323-328.  
591 [10.1038/s41586-019-1457-z](https://doi.org/10.1038/s41586-019-1457-z).
- 592 27. Coltell, O., Sorli, J.V., Asensio, E.M., Barragan, R., Gonzalez, J.I., Gimenez-Alba, I.M.,  
593 Zanon-Moreno, V., Estruch, R., Ramirez-Sabio, J.B., Pascual, E.C., et al. (2020). Genome-  
594 Wide Association Study for Serum Omega-3 and Omega-6 Polyunsaturated Fatty Acids:  
595 Exploratory Analysis of the Sex-Specific Effects and Dietary Modulation in  
596 Mediterranean Subjects with Metabolic Syndrome. *Nutrients* *12*. [10.3390/nu12020310](https://doi.org/10.3390/nu12020310).
- 597 28. Riveros-Mckay, F., Oliver-Williams, C., Karthikeyan, S., Walter, K., Kundu, K., Ouweland,  
598 W.H., Roberts, D., Di Angelantonio, E., Soranzo, N., Danesh, J., et al. (2020). The  
599 influence of rare variants in circulating metabolic biomarkers. *PLoS Genet* *16*, e1008605.  
600 [10.1371/journal.pgen.1008605](https://doi.org/10.1371/journal.pgen.1008605).
- 601 29. Li-Gao, R., Hughes, D.A., van Klinken, J.B., de Mutsert, R., Rosendaal, F.R., Mook-  
602 Kanamori, D.O., Timpson, N.J., and Willems van Dijk, K. (2021). Genetic Studies of  
603 Metabolomics Change After a Liquid Meal Illuminate Novel Pathways for Glucose and  
604 Lipid Metabolism. *Diabetes* *70*, 2932-2946. [10.2337/db21-0397](https://doi.org/10.2337/db21-0397).
- 605 30. Richardson, T.G., Leyden, G.M., Wang, Q., Bell, J.A., Elsworth, B., Davey Smith, G., and  
606 Holmes, M.V. (2022). Characterising metabolomic signatures of lipid-modifying  
607 therapies through drug target mendelian randomisation. *PLoS Biol* *20*, e3001547.  
608 [10.1371/journal.pbio.3001547](https://doi.org/10.1371/journal.pbio.3001547).
- 609 31. Yin, X., Chan, L.S., Bose, D., Jackson, A.U., VandeHaar, P., Locke, A.E., Fuchsberger, C.,  
610 Stringham, H.M., Welch, R., Yu, K., et al. (2022). Genome-wide association studies of  
611 metabolites in Finnish men identify disease-relevant loci. *Nat Commun* *13*, 1644.  
612 [10.1038/s41467-022-29143-5](https://doi.org/10.1038/s41467-022-29143-5).
- 613 32. Montasser, M.E., Aslibekyan, S., Srinivasasainagendra, V., Tiwari, H.K., Patki, A., Bagheri,  
614 M., Kind, T., Barupal, D.K., Fan, S., Perry, J., et al. (2022). An Amish founder population  
615 reveals rare-population genetic determinants of the human lipidome. *Commun Biol* *5*,  
616 334. [10.1038/s42003-022-03291-2](https://doi.org/10.1038/s42003-022-03291-2).

- 617 33. Francis, M., Sun, Y., Xu, H., Brenna, J.T., and Ye, K. (2022). Fifty-one novel and replicated  
618 GWAS loci for polyunsaturated and monounsaturated fatty acids in 124,024 Europeans.  
619 medRxiv, 2022.2005.2027.22275343. 10.1101/2022.05.27.22275343.
- 620 34. Borges, M.C., Haycock, P.C., Zheng, J., Hemani, G., Holmes, M.V., Davey Smith, G.,  
621 Hingorani, A.D., and Lawlor, D.A. (2022). Role of circulating polyunsaturated fatty acids  
622 on cardiovascular diseases risk: analysis using Mendelian randomization and fatty acid  
623 genetic association data from over 114,000 UK Biobank participants. *BMC Med* 20, 210.  
624 10.1186/s12916-022-02399-w.
- 625 35. Liu, C., Wang, Z., Hui, Q., Chiang, Y., Chen, J., Brijkumar, J., Edwards, J.A., Ordonez, C.E.,  
626 Dudgeon, M.R., Sunpath, H., et al. (2022). Crosstalk between Host Genome and  
627 Metabolome among People with HIV in South Africa. *Metabolites* 12.  
628 10.3390/metabo12070624.
- 629 36. Davyson, E., Shen, X., Gadd, D.A., Bernabeu, E., Hillary, R.F., McCartney, D.L., Adams, M.,  
630 Marioni, R., and McIntosh, A.M. (2023). Metabolomic Investigation of Major Depressive  
631 Disorder Identifies a Potentially Causal Association With Polyunsaturated Fatty Acids.  
632 *Biol Psychiatry* 94, 630-639. 10.1016/j.biopsych.2023.01.027.
- 633 37. Fuller, H., Iles, M.M., Moore, J.B., and Zulyniak, M.A. (2023). Metabolic drivers of  
634 dysglycemia in pregnancy: ethnic-specific GWAS of 146 metabolites and 1-sample  
635 Mendelian randomization analyses in a UK multi-ethnic birth cohort. *Front Endocrinol*  
636 (Lausanne) 14, 1157416. 10.3389/fendo.2023.1157416.
- 637 38. Karjalainen, M.K., Karthikeyan, S., Oliver-Williams, C., Sliz, E., Allara, E., Fung, W.T.,  
638 Surendran, P., Zhang, W., Jousilahti, P., Kristiansson, K., et al. (2024). Genome-wide  
639 characterization of circulating metabolic biomarkers. *Nature* 628, 130-138.  
640 10.1038/s41586-024-07148-y.
- 641 39. Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P.,  
642 Green, J., Landray, M., et al. (2015). UK biobank: an open access resource for identifying  
643 the causes of a wide range of complex diseases of middle and old age. *PLoS Med* 12,  
644 e1001779. 10.1371/journal.pmed.1001779.
- 645 40. Pan-ancestry genetic analysis of the UK Biobank. <https://pan.ukbb.broadinstitute.org/>.
- 646 41. Julkunen, H., Cichonska, A., Slagboom, P.E., Wurtz, P., and Nightingale Health, U.K.B.I.  
647 (2021). Metabolic biomarker profiling for identification of susceptibility to severe  
648 pneumonia and COVID-19 in the general population. *Elife* 10. 10.7554/eLife.63033.
- 649 42. McCaw, Z.R., Lane, J.M., Saxena, R., Redline, S., and Lin, X. (2020). Operating  
650 characteristics of the rank-based inverse normal transformation for quantitative trait  
651 analysis in genome-wide association studies. *Biometrics* 76, 1262-1272.  
652 10.1111/biom.13214.
- 653 43. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A.,  
654 Vukcevic, D., Delaneau, O., O'Connell, J., et al. (2018). The UK Biobank resource with  
655 deep phenotyping and genomic data. *Nature* 562, 203-209. 10.1038/s41586-018-0579-z.
- 656 44. Jiang, L., Zheng, Z., Qi, T., Kemper, K.E., Wray, N.R., Visscher, P.M., and Yang, J. (2019). A  
657 resource-efficient tool for mixed model association analysis of large-scale data. *Nat*  
658 *Genet* 51, 1749-1755. 10.1038/s41588-019-0530-8.
- 659 45. International HapMap, C., Altshuler, D.M., Gibbs, R.A., Peltonen, L., Altshuler, D.M.,  
660 Gibbs, R.A., Peltonen, L., Dermitzakis, E., Schaffner, S.F., Yu, F., et al. (2010). Integrating

- 661 common and rare genetic variation in diverse human populations. *Nature* 467, 52-58.  
662 10.1038/nature09298.
- 663 46. Yang, J., Zaitlen, N.A., Goddard, M.E., Visscher, P.M., and Price, A.L. (2014). Advantages  
664 and pitfalls in the application of mixed-model association methods. *Nat Genet* 46, 100-  
665 106. 10.1038/ng.2876.
- 666 47. Jordan, H., Roderick, P., and Martin, D. (2004). The Index of Multiple Deprivation 2000  
667 and accessibility effects on health. *J Epidemiol Community Health* 58, 250-257.  
668 10.1136/jech.2003.013011.
- 669 48. Cleland, C., Ferguson, S., Ellis, G., and Hunter, R.F. (2018). Validity of the International  
670 Physical Activity Questionnaire (IPAQ) for assessing moderate-to-vigorous physical  
671 activity and sedentary behaviour of older adults in the United Kingdom. *BMC Med Res*  
672 *Methodol* 18, 176. 10.1186/s12874-018-0642-3.
- 673 49. Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., Klemm, A., Flicek,  
674 P., Manolio, T., Hindorff, L., and Parkinson, H. (2014). The NHGRI GWAS Catalog, a  
675 curated resource of SNP-trait associations. *Nucleic Acids Res* 42, D1001-1006.  
676 10.1093/nar/gkt1229.
- 677 50. Manolio, T.A., Collins, F.S., Cox, N.J., Goldstein, D.B., Hindorff, L.A., Hunter, D.J.,  
678 McCarthy, M.I., Ramos, E.M., Cardon, L.R., Chakravarti, A., et al. (2009). Finding the  
679 missing heritability of complex diseases. *Nature* 461, 747-753. 10.1038/nature08494.
- 680 51. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller, J.,  
681 Sklar, P., de Bakker, P.I., Daly, M.J., and Sham, P.C. (2007). PLINK: a tool set for whole-  
682 genome association and population-based linkage analyses. *Am J Hum Genet* 81, 559-  
683 575. 10.1086/519795.
- 684 52. McLaren, W., Pritchard, B., Rios, D., Chen, Y., Flicek, P., and Cunningham, F. (2010).  
685 Deriving the consequences of genomic variants with the Ensembl API and SNP Effect  
686 Predictor. *Bioinformatics* 26, 2069-2070. 10.1093/bioinformatics/btq330.
- 687 53. Bulik-Sullivan, B.K., Loh, P.R., Finucane, H.K., Ripke, S., Yang, J., Schizophrenia Working  
688 Group of the Psychiatric Genomics, C., Patterson, N., Daly, M.J., Price, A.L., and Neale,  
689 B.M. (2015). LD Score regression distinguishes confounding from polygenicity in  
690 genome-wide association studies. *Nat Genet* 47, 291-295. 10.1038/ng.3211.
- 691 54. Bulik-Sullivan, B., Finucane, H.K., Anttila, V., Gusev, A., Day, F.R., Loh, P.R., ReproGen, C.,  
692 Psychiatric Genomics, C., Genetic Consortium for Anorexia Nervosa of the Wellcome  
693 Trust Case Control, C., Duncan, L., et al. (2015). An atlas of genetic correlations across  
694 human diseases and traits. *Nat Genet* 47, 1236-1241. 10.1038/ng.3406.
- 695 55. Weissbrod, O., Hormozdiari, F., Benner, C., Cui, R., Ulirsch, J., Gazal, S., Schoech, A.P.,  
696 van de Geijn, B., Reshef, Y., Marquez-Luna, C., et al. (2020). Functionally informed fine-  
697 mapping and polygenic localization of complex trait heritability. *Nat Genet* 52, 1355-  
698 1363. 10.1038/s41588-020-00735-5.
- 699 56. Loh, P.R., Kichaev, G., Gazal, S., Schoech, A.P., and Price, A.L. (2018). Mixed-model  
700 association for biobank-scale datasets. *Nat Genet* 50, 906-908. 10.1038/s41588-018-  
701 0144-6.
- 702 57. Foley, C.N., Staley, J.R., Breen, P.G., Sun, B.B., Kirk, P.D.W., Burgess, S., and Howson,  
703 J.M.M. (2021). A fast and efficient colocalization algorithm for identifying shared genetic  
704 risk factors across multiple traits. *Nat Commun* 12, 764. 10.1038/s41467-020-20885-8.

- 705 58. Wang, G., Sarkar, A., Carbonetto, P., and Stephens, M. (2020). A simple new approach to  
706 variable selection in regression, with application to genetic fine mapping. *J R Stat Soc*  
707 *Series B Stat Methodol* 82, 1273-1300. [10.1111/rssb.12388](https://doi.org/10.1111/rssb.12388).
- 708 59. Watanabe, K., Taskesen, E., van Bochoven, A., and Posthuma, D. (2017). Functional  
709 mapping and annotation of genetic associations with FUMA. *Nat Commun* 8, 1826.  
710 [10.1038/s41467-017-01261-5](https://doi.org/10.1038/s41467-017-01261-5).
- 711 60. Lee, S.H., Wray, N.R., Goddard, M.E., and Visscher, P.M. (2011). Estimating missing  
712 heritability for disease from genome-wide association studies. *Am J Hum Genet* 88, 294-  
713 305. [10.1016/j.ajhg.2011.02.002](https://doi.org/10.1016/j.ajhg.2011.02.002).
- 714 61. Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., and  
715 Mesirov, J.P. (2011). Molecular signatures database (MSigDB) 3.0. *Bioinformatics* 27,  
716 1739-1740. [10.1093/bioinformatics/btr260](https://doi.org/10.1093/bioinformatics/btr260).
- 717 62. Wu, Y., Qi, T., Wray, N.R., Visscher, P.M., Zeng, J., and Yang, J. (2023). Joint analysis of  
718 GWAS and multi-omics QTL summary statistics reveals a large fraction of GWAS signals  
719 shared with molecular phenotypes. *Cell Genom* 3, 100344. [10.1016/j.xgen.2023.100344](https://doi.org/10.1016/j.xgen.2023.100344).
- 720 63. Vosa, U., Claringbould, A., Westra, H.J., Bonder, M.J., Deelen, P., Zeng, B., Kirsten, H.,  
721 Saha, A., Kreuzhuber, R., Yazar, S., et al. (2021). Large-scale cis- and trans-eQTL analyses  
722 identify thousands of genetic loci and polygenic scores that regulate blood gene  
723 expression. *Nat Genet* 53, 1300-1310. [10.1038/s41588-021-00913-z](https://doi.org/10.1038/s41588-021-00913-z).
- 724 64. Sun, B.B., Chiou, J., Traylor, M., Benner, C., Hsu, Y.H., Richardson, T.G., Surendran, P.,  
725 Mahajan, A., Robins, C., Vasquez-Grinnell, S.G., et al. (2023). Plasma proteomic  
726 associations with genetics and health in the UK Biobank. *Nature* 622, 329-338.  
727 [10.1038/s41586-023-06592-6](https://doi.org/10.1038/s41586-023-06592-6).
- 728 65. Wu, Y., Zeng, J., Zhang, F., Zhu, Z., Qi, T., Zheng, Z., Lloyd-Jones, L.R., Marioni, R.E.,  
729 Martin, N.G., Montgomery, G.W., et al. (2018). Integrative analysis of omics summary  
730 data reveals putative mechanisms underlying complex traits. *Nat Commun* 9, 918.  
731 [10.1038/s41467-018-03371-0](https://doi.org/10.1038/s41467-018-03371-0).
- 732 66. McRae, A.F., Marioni, R.E., Shah, S., Yang, J., Powell, J.E., Harris, S.E., Gibson, J., Henders,  
733 A.K., Bowdler, L., Painter, J.N., et al. (2018). Identification of 55,000 Replicated DNA  
734 Methylation QTL. *Sci Rep* 8, 17605. [10.1038/s41598-018-35871-w](https://doi.org/10.1038/s41598-018-35871-w).
- 735 67. Consortium, G.T. (2020). The GTEx Consortium atlas of genetic regulatory effects across  
736 human tissues. *Science* 369, 1318-1330. [10.1126/science.aaz1776](https://doi.org/10.1126/science.aaz1776).
- 737 68. Chen, L., Ge, B., Casale, F.P., Vasquez, L., Kwan, T., Garrido-Martin, D., Watt, S., Yan, Y.,  
738 Kundu, K., Ecker, S., et al. (2016). Genetic Drivers of Epigenetic and Transcriptional  
739 Variation in Human Immune Cells. *Cell* 167, 1398-1414 e1324.  
740 [10.1016/j.cell.2016.10.026](https://doi.org/10.1016/j.cell.2016.10.026).
- 741 69. Kumasaka, N., Knights, A.J., and Gaffney, D.J. (2019). High-resolution genetic mapping of  
742 putative causal interactions between regions of open chromatin. *Nat Genet* 51, 128-137.  
743 [10.1038/s41588-018-0278-6](https://doi.org/10.1038/s41588-018-0278-6).
- 744 70. Goldstein, J.L., and Brown, M.S. (2009). The LDL receptor. *Arterioscler Thromb Vasc Biol*  
745 29, 431-438. [10.1161/ATVBAHA.108.179564](https://doi.org/10.1161/ATVBAHA.108.179564).
- 746 71. Naik, A., Kosir, R., and Rozman, D. (2013). Genomic aspects of NAFLD pathogenesis.  
747 *Genomics* 102, 84-95. [10.1016/j.ygeno.2013.03.007](https://doi.org/10.1016/j.ygeno.2013.03.007).

- 748 72. Gao, L., Tse, S.W., Conrad, C., and Andreadis, A. (2005). Saitohin, which is nested in the  
749 tau locus and confers allele-specific susceptibility to several neurodegenerative diseases,  
750 interacts with peroxiredoxin 6. *J Biol Chem* *280*, 39268-39272. [10.1074/jbc.M506116200](https://doi.org/10.1074/jbc.M506116200).
- 751 73. Schulze, M.B., Minihane, A.M., Saleh, R.N.M., and Riserus, U. (2020). Intake and  
752 metabolism of omega-3 and omega-6 polyunsaturated fatty acids: nutritional  
753 implications for cardiometabolic diseases. *Lancet Diabetes Endocrinol* *8*, 915-930.  
754 [10.1016/S2213-8587\(20\)30148-0](https://doi.org/10.1016/S2213-8587(20)30148-0).
- 755 74. Gretarsdottir, S., Helgason, H., Helgadóttir, A., Sigurdsson, A., Thorleifsson, G.,  
756 Magnúsdóttir, A., Oddsson, A., Steinthorsdóttir, V., Rafnar, T., de Graaf, J., et al. (2015).  
757 A Splice Region Variant in LDLR Lowers Non-high Density Lipoprotein Cholesterol and  
758 Protects against Coronary Artery Disease. *PLoS Genet* *11*, e1005379.  
759 [10.1371/journal.pgen.1005379](https://doi.org/10.1371/journal.pgen.1005379).
- 760 75. Raben, D.M., and Tu-Sekine, B. (2008). Nuclear diacylglycerol kinases: regulation and  
761 roles. *Front Biosci* *13*, 590-597. [10.2741/2704](https://doi.org/10.2741/2704).
- 762 76. Sadafi, S., Choubasaz, P., Kazemeini, S.M.M., Imani, M.M., and Sadeghi, M. (2024).  
763 Glutathione S-transferase theta 1 (GSTT1) deletion polymorphism and susceptibility to  
764 head and neck carcinoma: a systematic review with five analyses. *BMC Cancer* *24*, 885.  
765 [10.1186/s12885-024-12618-7](https://doi.org/10.1186/s12885-024-12618-7).
- 766 77. Ashida, S., Orloff, M.S., Bebek, G., Zhang, L., Zheng, P., Peehl, D.M., and Eng, C. (2012).  
767 Integrated analysis reveals critical genomic regions in prostate tumor microenvironment  
768 associated with clinicopathologic phenotypes. *Clin Cancer Res* *18*, 1578-1587.  
769 [10.1158/1078-0432.CCR-11-2535](https://doi.org/10.1158/1078-0432.CCR-11-2535).
- 770 78. Zhou, T.B., Drummen, G.P., Jiang, Z.P., and Qin, Y.H. (2014). GSTT1 polymorphism and  
771 the risk of developing prostate cancer. *Am J Epidemiol* *180*, 1-10. [10.1093/aje/kwu112](https://doi.org/10.1093/aje/kwu112).
- 772 79. Liu, D., Che, B., Chen, P., He, J., Mu, Y., Chen, K., Zhang, W., Xu, S., and Tang, K. (2022).  
773 GSTT1, an increased risk factor for prostate cancer in patients with metabolic syndrome.  
774 *J Clin Lab Anal* *36*, e24352. [10.1002/jcla.24352](https://doi.org/10.1002/jcla.24352).
- 775 80. Zhang, Y., Sun, Y., Song, S., Khankari, N.K., Brenna, J.T., Shen, Y., and Ye, K. (2024).  
776 Associations of plasma omega-6 and omega-3 fatty acids with overall and 19 site-  
777 specific cancers: A population-based cohort study in UK Biobank. *Int J Cancer*.  
778 [10.1002/ijc.35226](https://doi.org/10.1002/ijc.35226).
- 779 81. Li, H., Herrmann, T., Seessle, J., Liebisch, G., Merle, U., Stremmel, W., and Chamulitrat,  
780 W. (2022). Role of fatty acid transport protein 4 in metabolic tissues: insights into  
781 obesity and fatty liver disease. *Biosci Rep* *42*. [10.1042/BSR20211854](https://doi.org/10.1042/BSR20211854).
- 782 82. Pingault, J.B., O'Reilly, P.F., Schoeler, T., Ploubidis, G.B., Rijdsdijk, F., and Dudbridge, F.  
783 (2018). Using genetic data to strengthen causal inference in observational research. *Nat*  
784 *Rev Genet* *19*, 566-580. [10.1038/s41576-018-0020-3](https://doi.org/10.1038/s41576-018-0020-3).
- 785 83. Tayefeh-Gholami, S., Ghanbari, M., Aghazadeh, A., Rajabi, A., Saber, A., Hussen, B.M.,  
786 Farsad-Akhtar, N., and Safaralizadeh, R. (2022). Prognostic Value of LncRNA KRT18P55 in  
787 Patients with Intestinal Type of Gastric Cancer. *J Gastrointest Cancer* *53*, 1014-1019.  
788 [10.1007/s12029-021-00744-5](https://doi.org/10.1007/s12029-021-00744-5).
- 789 84. Tillander, V., Arvidsson Nordstrom, E., Reilly, J., Strozyk, M., Van Veldhoven, P.P., Hunt,  
790 M.C., and Alexson, S.E. (2014). Acyl-CoA thioesterase 9 (ACOT9) in mouse may provide a



- 791 novel link between fatty acid and amino acid metabolism in mitochondria. *Cell Mol Life*  
792 *Sci* 71, 933-948. 10.1007/s00018-013-1422-1.
- 793 85. Welty, F.K., Daher, R., and Garelnabi, M. (2024). Fish and Omega-3 Fatty Acids: Sex and  
794 Racial Differences in Cardiovascular Outcomes and Cognitive Function. *Arterioscler*  
795 *Thromb Vasc Biol* 44, 89-107. 10.1161/ATVBAHA.122.318125.
- 796 86. Jankowich, M., and Choudhary, G. (2020). Endothelin-1 levels and cardiovascular events.  
797 *Trends Cardiovasc Med* 30, 1-8. 10.1016/j.tcm.2019.01.007.
- 798 87. Davegardh, C., Sall, J., Benrick, A., Broholm, C., Volkov, P., Perfilyev, A., Henriksen, T.I.,  
799 Wu, Y., Hjort, L., Brons, C., et al. (2021). VPS39-deficiency observed in type 2 diabetes  
800 impairs muscle stem cell differentiation via altered autophagy and epigenetics. *Nat*  
801 *Commun* 12, 2431. 10.1038/s41467-021-22068-5.

## Figure Captions

### Main Figures

**Figure 1. Manhattan plot of the genome-wide association studies for the absolute concentration of total polyunsaturated fatty acids.** (A and B) The association of each variant with polyunsaturated fatty acids was obtained from genome-wide association studies using models 2 (A) and 3 (B). A variant with a  $P$ -value below  $5 \times 10^{-8}$  was considered statistically significant. The nearest gene at each genome-wide significant locus is annotated, in black for known loci and in red for novel loci.

**Figure 2. Miami plot of the absolute concentration of total polyunsaturated fatty acids from genome-wide association studies using model 2.** The top panel shows the GWAS results in females, while the bottom panel shows the GWAS results in males. The  $-\log_{10}(P\text{-value})$  is plotted on the y-axis and chromosomal location is plotted on the x-axis. The genome-wide significance threshold ( $P\text{-value} < 5 \times 10^{-8}$ ) is indicated by the red dashed line. The nearest gene at each genome-wide significant locus is annotated, in black for known loci and in red for novel loci. Note that the lead variant (rs165527) from the novel locus on chromosome 10 (chr10:17259567-17325281) is not shown in the figure because it is an intergenic variant without an associated gene.

**Figure 3. Pathway enrichment analysis of the absolute concentration of total polyunsaturated fatty acids from genome-wide association studies using model 2.** Treemap depicting significantly enriched pathways at an adjusted  $P$ -value threshold of 0.05. Gene ontology terms were clustered based on semantic similarity, with terms displayed as individual


rectangles. The color indicates cluster membership, and thick border lines differentiate clusters. The size of each rectangle represents the enrichment significance, and the most significantly enriched term in each cluster is highlighted in white text as the representative term.

**Figure 4. Number of loci for fatty acid traits associated with different molecular phenotype combinations.** (A and B) The number of loci associated with 19 fatty acid traits and molecular quantitative trait loci (xQTLs) was determined based on genome-wide association studies using models 2 (A) and 3 (B). The loci numbers are based on significant OPERA association results that pass a posterior probability of association threshold of 0.9 and the multi-exposure heterogeneity in dependent instruments (HEIDI) test ( $P_{\text{HEIDI}} > 0.01$ ). The x-axis represents the association hypotheses for different phenotype combinations, while the y-axis shows the number of loci associated with these combinations across 19 fatty acids. Each violin plot displays the distribution of loci numbers by width, with lines indicating the 25<sup>th</sup> percentile, median, and 75<sup>th</sup> percentile.

**Figure 5. Prioritization of a locus near the *GSTT1/2/2B* genes for the absolute concentration of total fatty acids.** The top track displays the  $-\log_{10}(P\text{-value})$  of GWAS SNPs (gray dots) for total fatty acids. Red diamonds indicate OPERA marginal PPA for gene associations using eQTL data, while blue circles show OPERA marginal PPA for associations with protein abundance, DNA methylation, RNA splicing, histone modification, and chromatin accessibility, respectively. The bottom track presents 14 chromatin state annotations inferred from the 127 samples of the Roadmap Epigenomics Mapping Consortium.




**Figure 2.**





**Figure 4.**



**Figure 5.**

